GSK plc (GSK) — SEC Filings

Latest SEC filings for GSK plc (GSK), explained in plain English.

Sentiment Overview: 4 bullish, 10 neutral

Recent Filings (14)

• 6-K Filing — 6-K · 2026-04-02T07:35:43-04:00 [neutral]
• 6-K Filing — 6-K · 2026-04-01T12:27:24-04:00 [neutral]
• GSK plc Files Share Transaction Report (6-K) — 6-K · 2026-04-01T06:58:45-04:00 [neutral] Risk: low
  GSK plc filed a Form 6-K on April 1, 2026, reporting a transaction involving its own shares. The filing, submitted on a.htm, details activities related to GSK's
• 6-K Filing — 6-K · 2026-04-01T06:37:51-04:00 [neutral]
• 6-K Filing — 6-K · 2026-03-31T06:16:09-04:00 [neutral]
• GSK's Bepirovirsen Accepted for Review in China — 6-K · 2026-03-30T06:50:09-04:00 [neutral] Risk: low
  GSK plc announced on March 30, 2026, that their investigational drug, bepirovirsen, has been accepted for review by China's National Medical Products Administra
• GSK's TRELEGY ELLIPTA approved for severe asthma in China — 6-K · 2026-03-30T06:35:43-04:00 [bullish] Risk: low
  GSK plc announced on March 30, 2026, that its treatment for severe asthma, 'TRELEGY ELLIPTA', has been approved in China. This approval is based on positive res
• GSK plc Files 6-K on Share Transaction — 6-K · 2026-03-30T06:24:19-04:00 [neutral] Risk: low
  On March 30, 2026, GSK plc filed a Form 6-K with the SEC, reporting a transaction involving its own shares. The filing, with SEC Accession No. 0001654954-26-002
• 6-K Filing — 6-K · 2026-03-27T07:43:56-04:00 [neutral]
• GSK's Bepirovirsen Accepted for EMA Review — 6-K · 2026-03-27T07:37:58-04:00 [neutral] Risk: low
  GSK plc announced on March 27, 2026, that their submission for Bepirovirsen has been accepted for review by the European Medicines Agency (EMA). This acceptance
• GSK Files 6-K on Own Share Transactions — 6-K · 2026-03-26T07:07:14-04:00 [bullish]
  GSK plc filed a 6-K on March 26, 2026, reporting a "TRANSACTION IN OWN SHARES." This filing indicates that GSK is likely repurchasing its own stock, which can r
• GSK plc Files 6-K for Annual General Meeting Notice — 6-K · 2026-03-25T09:23:38-04:00 [neutral]
  GSK plc, a pharmaceutical giant, filed a 6-K on March 25, 2026, to announce its Notice of Annual General Meeting (AGM). This filing, identified by accession num
• GSK plc Reports Transaction in Own Shares on March 25, 2026 — 6-K · 2026-03-25T06:58:55-04:00 [bullish]
  GSK plc filed a 6-K on March 25, 2026, reporting a "TRANSACTION IN OWN SHARES." This filing indicates that GSK is likely repurchasing its own stock, which can r
• GSK Reports Own Share Transaction on March 24, 2026 — 6-K · 2026-03-24T07:39:22-04:00 [bullish]
  GSK plc filed a 6-K on March 24, 2026, reporting a "TRANSACTION IN OWN SHARES." This filing indicates that GSK is likely repurchasing its own stock, which can r